M&A / Deals Novartis to acquire Myricx Bio in up to $1.5bn deal Pharmaceutical Business ReviewThe deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments.OncologyRead full story pharminent July 6, 2026 (Last updated: July 6, 2026) Pharmaceutical Business Review The deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Roche looks to Astex in $515m breast cancer dealNext: Novartis Acquires UK ADC Specialist Myricx Bio for Up to $1.5 Billion Related Stories M&A / Deals Repligen builds in cell therapy with $1.5bn BioLife takeover pharminent July 22, 2026 M&A / Deals Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics pharminent July 20, 2026 M&A / Deals Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal pharminent July 20, 2026
